Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB264 and SKB118 in Advanced NSCLC
NCT07697586Phase 2Recruiting
- Sponsor
- Kelun-Biotech
- Start
- Aug 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab tirumotecan, CR-001 in non-small cell lung cancer (NSCLC), sponsored by Kelun-Biotech. Started Aug 2026; status: recruiting.
02
Drugs
sacituzumab tirumotecanCR-001
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07697586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07697586.